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ABSTRACT 
Dependence from addictive substances is a serious public health concern in the 
United States. Alcohol appears to be the most popular abused substance, while cigarette 
smoking has the highest rates of mortality. Though not as popular, illicit drugs such as 
cocaine and opioids are able to cause incredible damage to the lives of addicted 
individuals and to the people around them. The toxic injuries produced in the brain and 
the presence of withdrawal symptoms often result in cognitive deficits. Individuals that 
are able to terminate the consumption of drugs often have a hard time regaining their 
previous cognitive abilities. This partially contributes to the high incidence of relapse, 
which represents a major problem faced by the medical community. So far treatment has 
relied on cognitive behavioral therapy and a number of pharmacological agents. Even 
when combined, these approaches have not yielded satisfying results. For some types of 
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addictions, such as the one for cocaine, there are no approved medications. Therefore 
research has made tremendous efforts to understand how the brain responds to addictive 
substances with the hope that such knowledge will lead to new pharmacological 
treatments. Cognitive enhancers are a promising class of drugs that is under investigation 
for the treatment of substance dependence. Most of them have been tested for their ability 
to decrease drug craving and consumption. Some of them are also being examined for 
their ability to reverse the cognitive deficits produced by previous drug exposure. The 
present thesis will examine the current literature on four cognitive enhancers: 
atomoxetine, reboxetine, selegiline and modafinil. Even if still in the preliminary stages, 
the clinical trials on reboxetine have obtained the highest rate of success. On the other 
hand, modafinil is the only cognitive enhancer that has been tested for reversing cognitive 
deficits. Compelling results in a clinical trial make modafinil one of the most exciting 
projects in this field of research. Atomoxetine and selegiline have mostly failed the 
clinical stage, but more studies are needed to determine their usefulness. In general, the 
potential ability to reverse cognitive deficits is not supported by the current literature and 
more research should be focused in this direction. 
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INTRODUCTION 
Definition of addiction 
The word addiction derives from the Latin verb addicere, to give up, to surrender. 
However, the term does not have a universal definition in the scientific field. Some 
experts argue that substance dependence refers to the tolerance and/or withdrawal 
symptoms associated with substance abuse, while the term addiction entails a broader 
variety of behavioral and physical manifestations (1 ). Other experts in the field believe 
that the terms addiction and dependence can be used interchangeably (2). This latter 
approach will be the one used in the present thesis. 
One of most authoritative definition is found in the Diagnostic and Statistical 
Manual of Mental Disorders (3). Substance dependence is described as a number of 
symptoms that prevent an individual from terminating the intake of a substance despite 
, 
numerous negative consequences. It is diagnosed when a patient fulfills three or more of 
the following criteria within a 12-month period (Table 1). 
Table 1. Criteria for substance dependence. In order to be diagnosed for substance 
dependence, a patient must meet three or more of the following criteria within a 12-month period 
of time. 
1 Tolerance, the intake of an increasingly higher quantity of a substance in order to 
achieve the desired effect. 
2 Withdrawal, a series of unpleasant feelings arising from a lack of substance intake. 
3 Impaired control, manifested as the unintentional use of a substance in larger 
quantities and for longer periods of time. 
4 Impaired control, manifested as the unsuccessful termination of a substance intake 
despite a conscious desire to do so. 
5 Longer time spent in trying to find a substance, using it and recuperating from its 
effects. 
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6 The loss of interest in relationships, work and hobbies. Attention is mostly directed 
to substance related activities. 
7 The inability to cease the use of a substance even in the clear presence of serious 
psychological and physical repercussions. 
The presence of these physical and behavioral conditions are consistent across different 
types of addictions. However, there is considerable variety in the severity of each 
category. For example, withdrawal symptoms are evident in a heroin addict, while almost 
undetectable in a marijuana user. 
An important feature of addiction that is not stressed enough in these 7 categories 
is relapse. In fact addiction is considered a chronic disorder, capable of affecting an 
individual even after a long period of abstinence. Relapse is by far the greatest problem 
that is being tackled by researchers and doctors in the field (1 ). The definitions presented 
above clearly suggest that addiction is a serious disorder. The most alarming facts about 
addiction will be examined by the following section. 
Societal impact of addiction 
Addiction is an enormous burden to society, having negative effects on health 
care, economy and legal system of a country. The following chart summarizes the 
prevalence of the most popular abused substances and the economic costs they have on 
the American society. 
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Table 2. Quantitative perspective on the societal impact of addiction. * (billions of dollars 
per year) 
Economic cost* Millions of users (2) Deaths per year 
Nicotine 193 (1) 69.6 443,000 (4) 
Alcohol 184.6 (2) 131.3 24,263 (5) 
Illicit drugs 180.9 (3) 22.6 37,485 (6) 
Although these statistics are of great value in assessing the problem of addiction, they do 
so only on a quantitative level. To have a better sense of the real burden, one must 
consider the economic costs on a qualitative level also. For example, in the 185 billion 
dollars spent due to alcohol addiction, statisticians have included damages such as to 
drunk driving. This already represents a huge portion of deaths in the US. Similarly, in 
the 181 billion dollars spent on illicit drug abuse, statisticians have included losses in 
productivity, such as the unyielding future of children whose parents became addicts. 
Furthermore, one must also consider the moral damages caused by addiction. 
Numbers will never be able to express this kind of burden. Yet, people that are affected 
by addiction directly or indirectly must be confronted with enormous psychological 
adversities. 
Therefore, finding a solution to this problem becomes an immediate priority for 
the American society. With such purpose in mind, scientists are studying new ways to 
treat addiction, since the current therapies are not doing enough to fight the problem. 
However, coming up with new treatments is only possible with a profound understanding 
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of the neurobiology of addiction. There is now a great deai of knowledge on the way that 
the brain responds to substances of abuse, which will be the topic of the next section. 
NEUROBIOLOGY OF ADDICTION 
Opioids 
The nucleus accumbens (NAc) is a brain region located in the ventral striatum and 
it has been associated with reward, motivation and drug addiction. Anatomically it is 
divided into the core and the shell subregions, which. are believed to be distinct in 
function and receptors expressed. The main type of afferent neurons originating in the 
NAc are the medium spiny neurons (MSNs), which use y-amino-butyric-acid (GABA) as 
their neurotransmitter. Firing of MSNs is regulated by presynaptic glutamate, 
acetylcholine (ACh) and GABA inputs. In turn, these presynaptic terminals are 
themselves highly modulated, for example by binding and activation of opioid receptors 
(7). 
Brundege and Williams (7) have carried out electrophysiological studies to better 
assess the function of opioids in the NAc. [Met]5enkephalin acetate (ME), an endogenous 
peptide selective for the f..L and o opioid receptor, was able to decrease AMP A receptor-
mediated excitatory postsynaptic potentials (EPSPs) by approximately 30% in MSNs of 
the NAc shell. In a second experiment ME inhibited glutamate mediated EPSPs and 
GABA mediated inhibitory postsynaptic potentials (IPSPs) in both the core and shell of 
the NAc. The inhibition of the IPSPs was greater in magnitude (47% - 68%) than the 
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inhibition of EPSPs (29% - 39%). Both experiments were repeated with an endogenous 
opioid peptide selective for the o receptor. However, in this condition the inhibition was 
not comparable to the one of ME. 
The results from these experiments shine some light on the possible ways in which 
opioids act on the brain. Increased excitation in the NAc is believed to represent a 
common effect exerted by addictive drugs. ME was able to inhibit IPSPs more than 
EPSPs, indicating that opioids might ultimately cause excitation of MSNs by removing 
GABAergic inhibition. A fmding worthy of attention from this publication is that the Jl 
opioid receptor seems to be the main type responsible for affecting the NAc, given that 
stimulation of the o opioid receptor did not have any effect. This was also confirmed by 
earlier studies (8). 
Aside from modulation produced by glutamate and GABA, neurons in the NAc are 
significantly affected by dopaminergic projections coming from the ventral tegmental 
area (VTA). Addictive drugs tend to increase the release of DA from these projections 
and increase excitation of MSNs. Britt and McGehee (9) have recently tried to elucidate 
how opioids affect this dopaminergic synapse. In their experiments endomorphine-1 
(EM) was used, a peptide selective for the J.L opioid receptor. Upon a single electrical 
stimulus, lj..tM of EM decreased the DA overflow by approximately 41% in the NAc 
shell. On the other hand, upon burst stimulation at of 25 Hz, the membrane potential 
profile of dopaminergic neurons did not change before and after the exposure to EM. 
Previous evidence has suggested that dopaminergic neurons in the striatum do not 
possess opioid receptors (1 0). To explain their findings, Britt and McGehee hypothesized 
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that opioids can affect the release of DA in the NAc by binding to receptors located on 
cholinergic neurons. Activation of J..l. opioid receptors on cholinergic intemeurons 
decreases the release of ACh, resulting in decreased activation of nAChRs on 
dopaminergic terminals and consequently a decrease in DA release. This mechanism of 
action is strikingly similar to that of nicotine, which is believed to desensitize the 
nAChRs. Britt and McGehee were able to demonstrate that EM-I decreases the firing rate 
of cholinergic intemeurons of the NAc. 
Dopaminergic neurons in the NAc are usually found in either of two states. During 
tonic activity, DA release is low and can be paralleled to 'background noise.' During 
phasic activity, DA release is high and it is often referred to as burst firing. A large 
difference in DA levels between these two states is particularly influential in the 
reinstatement of an addiction. Therefore addictive drugs can increase this difference by 
either enhancing burst firing or by lowering tonic activity. The results obtained by Britt 
and McGehee indicate that opioids operate through the second mechanism. In fact, EM-1 
attenuated DA overflow upon a single stimulus, but did not affect the DA release upon 
burst firing. 
To summarize, opioids are likely to exert their function in the NAc by: 1) 
inhibiting GABAergic IPSPs on MSNs and 2) inhibiting cholinergic modulation of DA 
terminals. These findings, while certainly insightful, do not seem to agree with other 
sources suggesting that opioids increase the extracellular levels of DA in the NAc. The 
authors address this concern by suggesting that an inhibition of tonic activity ultimately 
leads to a higher frequency of burst firing and therefore higher levels ofDA. This can be 
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explained by hypothesizing that the removal of tonic activity removes the concerted 
activation of D1 and D2 receptors on GABAergic MSNs that project to the VTA. The 
removal of this activation could thus represent a removal of inhibition and an increase in 
burst firing activity. The results gathered by Britt and McGehee are compelling, but their 
claims remain hypothetical and still need further validation. 
Alcohol 
While most addictive substances are believed to excite the VTA and the NAc 
through indirect means, ethanol seems to have a direct action on dopaminergic neurons. 
In these type of cells, hyperpolarization causes the opening of Ih cation channels, 
resulting in a spontaneous low frequency depolarization similar to the one found in 
pacemaker cells. Okamoto et al. (11) have carried out electrophysiological experiments 
on mouse brain slices containing VTA and substantia nigra (SNc) neurons to assess the 
effects of ethanol on Ih channels. Superfusion of brain slices with ethanol causing a 
concentration of 50 mM increased the firing rate by 10.2% and augmented the cation 
current amplitude by 11. 7%. On the other hand 20 mM produced only a 5% increase in 
the firing rate and did not affect the amplitude of the cation current. ZD7288 (30 J.tM), an 
inhibitor of Ih channels, was able to suppress the firing frequency of DA neurons, 
indicating that the Ih channels were responsible for the pacemaker activity. Furthermore, 
to assess the effects of repeated alcohol use, mice were injected a dose of ethanol for five 
consecutive days, resulting in a plasma concentration of 50 mM. The density of Ih 
channels decreased from 11.4 to 8.8 pA/pF. The half activation potential and activation 
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kinetics did not change, suggesting that the properties of the channel itself were not 
affected. 
Following the rationale of the authors, this data indicated that alcohol increased 
basal activity of dopaminergic neurons in the VTA and SNc by acting on Ih channels. In 
addition, alcohol developed tolerance by decreasing the density of these channels after 
repeated use. This could explain the decreased DA levels found in the midbrain during 
withdrawal from drinking. However, all of these claims remain of uncertain validity due 
to the fact that the ethanol concentration used in the study were relatively high. With such 
elevated levels of alcohol, specificity is lost, a scenario that is not a good representation 
of what happens in recreational drinking. 
Another molecular target of ethanol that has received a lot of attention is the 
GABAergic neuron of the VTA. This type of cell is known to inhibit DA neurons that 
project to the NAc. The GABA neurons of the VTA are in turn excited by NMDA and 
inhibited by GABAA receptor activation. Stobbs et al. (12) have carried out in vivo 
experiments to elucidate the function of ethanol on GABA neurons. 0.25, 1 and 2 mg/kg 
of ethanol (comparable to plasma levels lower than 50mM) dose dependently decreased 
internal capsule stimulus induced poststimulus spike discharge (ICPSD) of VTA GABA 
neurons. Substituting the GABAA receptor agonist muscimol for ethanol did not cause 
comparable decreases in ICPSD, suggesting that ethanol does not bind to the GABAA 
receptor. However~ the GABAA receptor could still have an indirect role in the 
modulation of neuronal activity induced by ethanol. On the other hand, NMDA was able 
to moderately but significantly increase ICPSD. Furthermore, the authors of the above 
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study observed that either doubling the concentration of the NMDA antagonist 
dizocilpine or adding an equivalent dose of ethanol caused very a similar increase in 
ICPSD inhibition. Together the results imply the possibility that ethanol can cause 
disinhibition ofVTA DA neurons by inhibiting NMDA receptor activation on the GABA 
neurons ofthe VTA. 
While the above study shows no evidence of ethanol acting on the GABAA 
receptors of the VTA, in the NAc this receptor seems to have an important role. 
Supporting this idea is an experiment carried out by Rewal et al. (14) demonstrating that 
GABAA receptors containing the a.4 subunit in the NAc shell play a significant role in the 
development of ethanol dependence. Rats infected with viral RNA interference reducing 
the expression of the a.4 subunit decreased alcohol intake and preference. While these 
findings contribute more information on the ways in which ethanol produces its effects, 
the experiments carried out by Rewal et al. also raise problematic questions. The finding 
that a.4 containing GABAA receptors mediate the addictive effects of ethanol contradicts 
previous established dogmas suggesting that excitation instead of inhibition in the NAc is 
responsible for the development of alcoholism. The literature reviewed above shows how , 
intricate the effects of ethanol are and that contradictions prevent its mechanism of action 




Amphetamines are one of the most diverse class of drugs, due not only to the wide 
variety of possible derivatives, but also to their numerous molecular targets. After the 
discovery that amphetamine can increase the levels of DA in the striatum (14) by 
inhibiting the DA transporter (DAT) (15), an impressive amount of literature has been 
devoted to elucidating its mechanism of action. Pifl and colleagues (16) examined the 
DA efflux induced by amphetamine on COS-7 cells expressing the human DAT and the 
human vesicular monoamine transporter 2 (VMA T2). In these cells amphetamine was 
able to dose-dependently release more than twice the amount of DA compared to cells 
transfected with only the DAT. On a qualitativ~ level, the pattern ofDA efflux over time 
was also influenced by the expression of these transporters. In DAT cells the release of 
DA induced by amphetamine reached a peak and then returned to baseline. On the other 
hand, the release ofDA in cells with DAT and VMAT2 was sustained after reaching its 
peak. The authors also noticed that amphetamine had a higher potency with DAT cells. 
Together these findings imply a number of possible mechanisms of action for 
amphetamine. The ability to release DA from intracellular storage vesicles can explain 
the additional DA released when cells possess VMAT2. The increased potency of 
amphetamine in cells expressing only the DAT is due to the fact that DA is limited to the 
cytoplasm. Releasing neurotransmitter in this case is more rapid compared to mobilizing 
DA stored in the vesicles. This confirms once again that amphetamine can release DA 
from intracellular vesicles. Finally, after observing that cocaine, a blocker of the DAT, 
did not cause any efflux of neurotransmitter in DAT cells, the authors hypothesized that 
amphetamine mediates the release ofDA by reversing the DAT. 
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Other studies on amphetamine have identified three additional molecular targets. 
One of them, tyrosine hydroxylase, is an enzyme that converts tyrosine into L-DOP A, a 
precursor ofDA. Larsen et al. (17) demonstrated a three fold increase in the amount ofL-
DOP A produced with a methamphetamine infusion compared to control. Another 
enzyme targeted by amphetamines is monoamine oxidase A, which is responsible for the 
breakdown of DA. Ramsay et al. (18) have shown that d-amphetamine maintains the 
reduced state of MAO-A by stabilizing the semiquinone form of FAD. Lastly, 
amphetamine has also been shown to bind the D2 autoreceptor. Schmitz and colleagues 
(19) have hypothesized that the increase in extracellular DA caused by amphetamine 
activates the D2 autoreceptor, which inhibits the exocytosis of DA in a negative feedback 
manner. Upon a single electrical stimulation, infusion of amphetamine decreased the 
amplitude ofDA efflux by 82%, concordant with an inhibition ofDA exocytosis. 
This finding is still in agreement with previous evidence showing that 
amphetamine can relocate DA from the vesicles to the cytosol. By doing so, only a small 
quantity ofDA gets released upon exocytosis. Schmitz et al. believe that D2 autoreceptor 
contributes to this decrease in DA exocytosis. To demonstrate this hypothesis, they 
repeated their experiment with the addition of sulpiride, a D2 receptor antagonist. The 
decrease in DA efflux only reached 47% compared to the previous 82%. To further 
confirm these findings, DA efflux was measured in D2 receptor knock-out mice. In these 
animals, DA released was decreased by only 23%. Therefore there is compelling 
evidence indicating that under the effects of amphetamine the D2 autoreceptor decreases 
exocytosis ofDA. 
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To summarize, amphetamine most likely exerts its effects by: 1) blocking the 
reuptake of DA through inhibition of the DAT; 2) increasing the efflux of DA by 
reversing the transport of the DAT; 3) mobilizing DA from intracellular storage vesicles 
to the cytoplasm; 4) increasing the production of DA by stimulating TH activity; 5) 
decreasing DA breakdown by inhibiting MAO-A; 6) decreasing the exocytosis ofDA by 
stimulating the D2 autoreceptor. While there seems to be an overall consensus on these 
molecular targets, debate continues to revolve around the exact biochemical mechanism 
that underlies the effects of amphetamine. For example, how amphetamine manages to 
release DA from storage vesicles remains unclear (41g). The answer to this question is 
now the focus of several recent projects. 
b. Cocaine 
Together with the amphetamines, cocaine is another psychostimulant that has been 
abused by millions of Americans for decades. After preliminary studies suggesting that 
the addictive properties of cocaine are mediated by a blockade of the DAT (20), Rocha et 
al. (21) investigated the ability of DAT knock out mice to self-administer cocaine. In 
their experiment, DAT-I- mice required significantly more time for establishing self-
administration of cocaine compared to wild-type animals, suggesting that the DAT has an 
important function in the initiation of dependence. However, once established., self-
administration in both groups was stable and dose dependent. The dorsolventral striatum 
of DAT-I- mice presented with higher basal levels of DA compared to wild-type mice 
and a cocaine injection was not able to cause significant changes. This is in contrast with 
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control animals in which cocaine causes DA levels to significantly increase from basal 
levels. Therefore, other molecular targets aside from the DA transporter contribute to the 
establishment of cocaine self-administration. To identify possible binding sites through 
autoradiography, the cocaine analog [125I]RTI-55 was used on striatal coronal slices. To 
show that [125I]RTI-55 was a good analog of cocaine, the authors demonstrated that 
pretreatment with cocaine eliminated any radioactive labeling. Significant binding of 
[125I]RTI-55 occurred in DAT knock out mice, while the serotonin transporter 
antagonist alaprocrate significantly decreased radioactive labeling. These results indicate 
that cocaine also binds to the serotonin transporter, which could therefore have a role in 
the initiation of self-administration. 
The above study also attempted to demonstrate that cocaine can bind to the NET, 
but a pretreatment with a NET inhibitor did not change the pattern of [125I]RTI-55 
binding. The involvement of this transporter in the addictive effects of cocaine has been 
controversial. Following an early study suggesting that cocaine is likely to possess an 
affinity for the NET (22), more recent publications have shown that noradrenergic 
transmission indeed has a significant role. In particular, Beveridge et al. (23) 
demonstrated that cocaine exposure alters the density of the NET in several brain regions. 
Using [3H]nisoxetine to localize the NET in brain slices of squirrel monkeys, the 
investigators observed that the hypothalamus presented with an increase in transporter 
density compared to the wild type animals. It is believed that cocaine could stimulate 
noradrenergic transmission to the hypothalamus, leading to an increase in the production 
of corticotropin releasing factor (CRF), a hormone associated with the initiation of drug 
13 
intake. Higher levels of NET were also found in the basolateral amygdala, enthorhinal 
cortex and hippocampus. The interconnection between these brain regions is associated 
with cognitive functions such as memory and learning. The effects of cocaine on these 
areas might explain the presence of cognitive deficits after the repeated exposure to the 
drug. 
From the above analysis it appears that cocaine produces its effects by interacting 
with all three monoamine transporters. Among them, the DAT remains the most 
influential one. Some studies have tried to gain a more in depth perspective on the 
alterations to the dopaminergic transmission. For example, Heien et al. (24) have 
analyzed the release of DA in the NAc after an infusion of cocaine in live rodents. Upon 
burst electrical stimuli applied to the SNc and VTA, cocaine increased the frequency and 
amplitude of DA concentration spikes. As mentioned in the review of opioids, burst 
firing has a central role in the reinstatement of substance dependence. However, the 
precise mechanisms that allow cocaine to promote burst firing remain elusive. 
Nicotine 
Cigarette smoking is one of the leading causes of death in the United States (25). 
The addictive substance contained in tobacco is nicotine. A clear description of how this 
compound acts on the brain has not been achieved yet. What makes this task difficult is 
the wide vanety of receptor subunits, which have specific distribution in different parts of 
the brain. The subunit composition of nAChRs determines the binding affinity, 
desensitization and downstream effects of nicotine. 
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One of the most comprehensive studies on nicotine's mechanism of action has 
been carried out by Mansvelder and colleagues (26). Their focus has been analyzing 
GABAergic and glutamatergic projections that regulate the DA neurons of the VTA. In 
one of their experiments on rat brains, they inserted a stimulating electrode in 
GABAergic neurons of the VTA and NAc, which are both lmown to generate IPSPs in 
dopaminergic neurons. They moderated the intensity of stimulation such that 
dopaminergic cells experienced IPSPs 50% of the times. In these conditions, nicotine was 
able to increase the frequency of IPSP above 50%, suggesting that it can promote 
GABAergic transmission and therefore cause a downstream inhibition of DA neurons. 
IPSPs were also augmented in frequency and amplitude. However, in 7 out of 11 cells, 
the frequency dropped below baseline after reaching a brief peak, suggesting a possible 
desensitization of nAChRs. Methyllycaconitine, which is selective for the a7 subunit of 
the nAChR, did not change the IPSPs generated by nicotine. Mecamylamine, selective 
for non a1 subunits, completely abolished the nicotine induced increase in IPSP. The 
same effect was also produced by dihydro-p-erythroidine hydrobromide, an agent 
selective for P2 subunits. To further confirm the desensitization of nAChRs on GABA 
neurons, the authors infused the brain slices with 250 nM of nicotine. The frequency of 
IPSPs increased transiently and soon after returned to baseline. Immediately following 
this infusion, an additional 1 11M was applied, but no change was observed. They then 
repeated the experiment by measuring EPSPs, a measure of glutamate induced excitation 
from the PFC. A 250 nM infusion of nicotine increased EPSPs, which remained elevated 
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and did not resume back to baseline levels. A subsequent 1 J.LM infusion of nicotine 
caused an even higher increase in EPSPs frequency. 
The above results support the hypothesis that nicotine increases dopaminergic 
transmission in the VTA by simultaneously potentiating glutamatergic input and 
inhibiting GABAergic input. The first is probably achieved by activation of a7 containing 
nAChR on presynaptic glutamate terminals, which do not appear to desensitize. This 
increased glutamate input is thought to produce long term potentiation on the DA neurons 
ofthe VTA. On the other hand, GABA neurons are first activated,' but then brought to a 
lower basal activity by desensitization of receptors most likely containing the ~2 subunit. 
Together these putative mechanism of action could explain the addictive properties of 
nicotine. 
In addition to glutamatergic and GABAergic neurons, nAChRs are also found on 
the DA neurons of the VTA. Activation of these receptors by cholinergic projections is 
believed to increase DA release. Zhang and Sulzer (27) have hypothesize~ that nicotine 
can directly affect the release of DA in the NAc by desensitizing nAChRs on DA 
terminals. For this purpose, stimulating electrodes were implanted in the NAc with the 
ability to generate activity similar to tonic or phasic activity. With a single stimulation, 
nicotine decreased the release of DA. However, the authors observed that the higher the 
frequency of stimulation, the lower the inhibition induced by nicotine. At the highest 
frequency, a condition which emulates phasic firing, nicotine had no effects. Therefore 
the results support the idea that nicotine increases the difference between the levels of 
DA released during tonic activity and burst firing. Because phasic activity has been 
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associated with reinstatement of drug addiction, nicotine appears to generate dependence 
by potentiating the impact of burst firing in the NAc. Research trying to elucidate the 
precise mechanism that is responsible for these effects is still underway. 
From biology to behavior 
One of the challenges in addiction research has been to explain how the 
neurochemical changes elicited by drugs ~an influence so drastically the behavior of a 
substance user. A number of models have been developed to pinpoint what exactly causes 
the transition from an occasional drug use to a compulsive addiction. 
The classical view suggests that the desire to experience euphoria is the reason for 
the repetitive consumption of substances. After prolonged use, tolerance starts to prevail 
and the euphoria previously experienced disappears almost completely. Instead, 
alleviating the anhedonic effects of withdrawal becomes the reason for the drug intake 
(1). 
The incentive salience model argues that drug craving - rather than reward -
constitutes the primary cause of an addiction. Therefore, a person can be drawn into 
repetitive substance use even without ever experiencing a pleasurable effect A simple 
feeling of 'wanting' is sufficient for an occasional drug use to develop into a full-blown 
substance dependence (1 ). 
The aberrant learning model is a compromise between these two theories. It states 
that after the perception of increased reward from a substance, the brain registers all of 
the environmental stimuli and conscious behaviors that best predict the procurement of 
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that substance. This newly acquired information could be the drive for the repetitive drug 
taking. Proponents of this theory believe that this mechanism of action is analogous the 
one that allows humans to procure food and sex (1 ). 
While a consensus has not been reached, it is possible that a combination of these 
theories might be the most valid model. Theoretically the hedonic effect, the drug 
'wanting' and the learning of drug-associated stimuli might act at different stages of the 
addiction. Another possibility is that some models might be more applicable to some 
individuals rather than others depending on their genotype. In fact the topic of individual 
susceptibility has received a great deal of attention among experts. While single genes 
fully responsible for an addictive trait have not been identified, experts agree on the 
importance of the genetic makeup in determining the likelihood of substance dependence 
within an individual (1 ). 
Currently approved medications 
Opioids 
Methadone was first approved in the US in 1947 (28). For the next fifty years it 
represented the only satisfactory treatment for opioid addiction. Methadone is a J..L-opioid 
receptor agonist (29). Although it has been shown to decrease substance craving in most 
patients, many still fail their therapy and continue to have withdrawal symptoms (30). 
Other studies have reported an increase in craving for heroin after an additional 
administration of methadone (31 ). Additional evidence for the incomplete efficacy of 
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methadone can be found in fMRI studies showing that drug cues increase the activity of 
brain regions that are associated with drug craving (32, 33). 
The urge to find an alternative treatment has led to the introduction of 
buprenorphine, a partial J.L-opioid receptor agonist. First approved in 1981 as an analgesic, 
it was used for the treatment of opioid addiction only after 2002 (34). Compared to 
methadone, some studies have shown that buprenorphine increases treatment retention 
(35), while other investigators obtained mixed results (36, 37). 
The FDA has also approved Naltrexone, a J.L-opioid receptor antagonist. However, 
because of its anhedonic effects, compliance has become a major problem. Sustained 
release formulations have been designed to avoid this issue, but their efficacy still needs 
to be proven (38). 
Alcohol 
There is evidence suggesting that ethanol might work by interfering with 
glutamatergic transmission. To address this problem, drug developers have created 
acamprosate, a partial agonist for the NMDA receptor (39). Acamprosate appears to 
reverse the changes in glutamate levels elicited by ethanol (29). Even though the 
mechanism of action is not completely elucidated, its efficacy has been well documented 
(40). 
A completely different molecular strategy is used by disulfiram. By inhibiting 
alcohol dehydrogenase, this medication increases the levels of acetaldehyde, one of the 
metabolites of ethanol (29). Acetaldehyde causes flushing, vomiting and other adverse 
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effects, thus making the consumption of an alcoholic beverage an unpleasant experience 
( 41 ). Although the efficacy of disulfiram in treating alcoholism has been demonstrated, 
compliance is achievable only with the most motivated patients. 
Naltrexone has also been approved for the treatment of alcoholism, but satisfying 
evidence on its efficacy is still warranted. Just like in the treatment of opioid addiction, 
the problem of compliance remains an important issue to be solved (29). 
Nicotine 
The nicotine gum was the first treatment approved for nicotine addiction. Since 
then, many other formulations have been marketed, with similar success rates. These 
medications, collectively known as nicotine replacement therapies, can increase the 
success rate of smoking cessation ( 42), but they fail to address other issues such as the 
long term prevention of relapse ( 43). 
Consequently, different pharmacological approaches have been developed. For 
example, bupropion is an antidepressant that increases the levels of dopamine in the shell 
of the NAc and decreases the brain reward threshold ( 44). Some studies have also 
suggested that bupropion can block the effects of nicotine by direct binding to neuronal 
nAChRs ( 45). On the clinical side, compliance rates for bupropion are better than 
placebo, but nicotine craving is not completely alleviated. In addition, bupropion 
decreases only some of the symptoms of nicotine withdrawal ( 46). . 
V arenicline was the last approved drug for smoking cessation. It binds to all 
subtypes of nAChR with varying potencies. The highest affinity was found to be with the 
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a.4P2 receptor, which is thought to mediate the rewarding effects of nicotine. As a partial 
agonist, varenicline inhibits the binding of nicotine and partially increases dopamine in 
the NAc, ameliorating withdrawals and craving from nicotine (47). On the clinical side, 
varenicline is more effective than other currently approved medications, even in the long 
term abstinence. However, a number of patients in these clinical trials have failed to 
adhere to the therapy. Some adverse effects have also been documented ( 48). 
Psychostimulants 
There are no approved medications for the treatment of illicit psychostimulant 
addiction (cocaine, amphetamine, 3,4-Methylenedioxymethamphetamine (MDMA) and 
methamphetamine). This is an alarming situation, as their use is widespread. Cocaine 
users of age 12 and older amounted to 1.5 million last year, about 6.6% of total illicit 
drug users (1). Cognitive based therapy, which can be considered similar to behavioral 
medicine, has been the only therapy used so far. While its efficacy is significant, 
additional treatment resources are needed. 
Comments 
Out of all the approved drugs reviewed above, almost half of them have appeared 
on the market only in the last decade. Granted their considerable efficacy, the potential 
armamentarium available to a doctor has grown substantially. Physicians can now 
establish a personalized therapeutic plan based on the characteristics of the patient. 
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Adverse effects, motivation, length of abstinence and presence of psychiatric disorders 
are factors that help to determine which pharmacological intervention to use. 
However, each of the drugs reviewed above has its own shortcomings. With some 
medications it is hard to achieve compliance, while others are limited by abuse potential. 
These difficulties are confirmed by the National Institute on Drug Abuse: last year 22.1 
million individuals have been classified as having substance abuse or substance 
dependence. The statistics have not changed significantly since 2002 (1 ). This suggests 
that the current treatments are not doing enough. In fact, even with the vast progress 
made in the development of new pharmacological agents, relapse prevention remains the 
greatest problem faced by both patients and doctors. In addition, given the economic 
impact that addiction has on society, finding new therapeutics becomes a necessity for the 
scientific community. The next section will examine ways in which scientists are 
attacking the problem. 
Pharmacological Strategies 
A substantial amount of information has been unraveled on the way that drugs of 
abuse cause changes in the neurochemistry of the brain. This has allowed for the 
emergence of new pharmacological strategies, so far with promising results. 
As previously discussed, increased dopamine release in the NAc is responsible for 
the rewarding and addictive effects of almost every substance of abuse. It follows that a 
successful strategy consists in using compounds that have similar molecular mechanisms 
on the NAc as the drug of abuse, with the exception of being safer, longer lasting and 
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providing an inferior hedonic effect. Longer half lives could keep the patient away from 
repetitive consumption of substances. On the other hand, a small rewarding effect can 
alleviate the withdrawal symptoms. Known as agonists, these drugs were the first 
pharmacological strategy adopted in the fight against addiction. Despite being the oldest 
strategy, new drugs are still being developed under this regime with significant results 
I 
(49). 
A completely different approach is adopted by antagonists, agents that bind to the 
same receptors as the drugs of abuse, but elicit no molecular effect. Antagonists thus 
prevent other substances from binding the receptor and keeps them from causing any 
effect. Antagonists can also bind to the drug of abuse itself and prevent it from reaching 
its target receptor. This pharmacokinetic approach, consisting of antibodies to a specific 
drug, has shown some promise but substantial challenges still persist ( 49). 
Partial agonists are agents that have properties of both agonists and- antagonists. 
They bind to the same receptors targeted by drugs of abuse but cause only a moderate 
rewarding effect. This is sufficient to alleviate withdrawal symptoms but also prevents 
the binding of other drugs, keeping the patient from relapsing into the addiction ( 49). 
The above strategies have relied on molecular mechanisms that target DA 
neurotransmission in the mesolimbic system. A different strategy is to focus on other 
neurotransmitters that indirectly affect dopaminergic neurons. For example, NE 
trafficking is implicated in the reinstatement of drug addiction caused by stress. Scientists 
have developed a2 agonists that reduce NE release from the locus ceruleus (LC) and 
decrease the reinstatement of heroin and alcohol addiction (50). 
23 
Another key player in the neurobiology of addiction is CRF. Animai studies 
suggest that CRF receptor antagonists can decrease the response to stress and therefore 
become a potential therapeutic strategy (51). 
Glutamate is another important neurotransmitter involved in addiction. Increased 
release from the PFC to the NAc is responsible for the loss of control over drug seeking 
behavior, craving and relapse. Due to the importance of this neurotransmitter system, 
essentially every receptor involved in glutamate trafficking has been targeted. NMDA 
receptor antagonist have shown some efficacy in reducing alcohol craving. Agents that 
increase extracellular glutamate by acting on the cystine-glutamate antiporter are 
clinically effective in cocaine and nicotine studies. Agonist of the group TI metabotropic 
glutamate receptors (mGluR) reduce drug seeking behavior for alcohol, nicotine and 
cocaine ( 49). Lastly, group I mGluR antagonists can decrease self administration of 
virtually all drugs in animal models (52). 
Although the above pharmacological strategies hold great promise, this thesis will 
focus on a different class of drugs: cognitive enhancers. Even though they have common 
features with the strategies reviewed above, they can be considered a separate category 
because of their specific goal in the treatment of addiction. 
The idea of using cognitive enhancers stems from the discovery that substance 
abusers have impaired cognitive functions such as learning, attention, memory, inhibitory 
control and decision-making (53). These mental functions are essential for a successful 
recovery, especially in cognitive based therapy (CBT). In fact, patients enrolled in CBT 
are required to learn new strategies to cope with their condition ( 49). A correlation study 
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found that cocaine users who drop out of CBT tend to have significantly lower scores on 
tests that measure cognitive functioning (54). Similar findings emerged from a study 
with alcoholics (55). Cognitive enhancers aim at restoring these cognitive deficits, 
allowing patients to make better choices and undergo a more successful therapy. This 
thesis will now make a thorough review of four cognitive enhancers that are currently 
being investigated. Publications on the mechanisms of action, animal studies and clinical 
trials will be evaluated. 
REVIEW OF COGNITIVE ENHANCERS FOR THE TREATMENT OF 
ADDICTION 
Atomoxetine 
Mechanism of action 
Cognitive functioning is a process mediated by the prefrontal cortex (PFC) 
through the interconnection of multiple neurotransmitters systems. Among them, 
norepinephrine (NE) plays an important role in working memory, attention and responses 
to sensory stimuli. These functions are impaired in a number of disorders, such as 
attention-deficit hyperactivity disorder (ADHD) and substance dependence. Atomoxetine 
is a new pharmacological agent approved for the treatment of ADHD, but it is still under 
investigation for the treatment of substance dependence (56). 
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Atomoxetine exerts its effects by selectively blocking the presynaptic NE uptake 
transporter and thus increasing the synaptic levels of NE. In order to demonstrate this 
specific mechanism of action, Bymaster et al. (56) employed cell lines expressing the 
human NE, serotonin (5-HT) and dopamine (DA) transporters and infused them with 
ATO. The measured dissociation constant (K.i) were 5, 77 and 1451 respectively, 
demonstrating the selectivity of ATO for the NE transporter. To assess the ability of ATO 
to increase extracellular NE in the PFC, male Sprague-Dawley rats were administered the 
neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4), an 
agent known for depleting extracellular NE. ATO was able to bring cortical NE levels 
back to baseline levels even in the presence of DSP-4. In a subsequent experiment, 
researchers measured the extracellular levels of NE and DA in the PFC after ATO 
administration. Levels increased by 243% and 251% compared to baseline, respectively, 
while serotonin did not change significantly from controls. In the striatum and nucleus 
accumbens, DA and serotonin did not increase from baseline levels. These findings 
indicate that ATO selectively acts on brain regions and neurotransmitters that are 
involved in cognitive function, while leaving reward pathways unaffected. Therefore, as a 
potential therapeutic agent for addiction, ATO demonstrates minimal abuse liability. 
A more recent publication has explored the effects of atomoxetine in other brain 
regions known to be affected by NE transmission. Sawnson and colleagues (57) have 
demonstrated that NE increases approximately by 200% of baseline levels in the PFC, 
occipital cortex, hypothalamus, hippocampus and cerebellum. This is in agreement with 
previous data suggesting that atomoxetine blocks the NET. In a second experiment, the 
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a2-adrenergic antagonist idazoxan was coadministered with atomoxetine and NE levels 
increased above 700% of baseline. The authors interpreted this outcome as evidence that 
the atomoxetine induced increase in NE is attenuated by a2 autoreceptor activation. This 
result contributes to better understand the mechanism of action of atomoxetine, but 
whether a combination of these two pharmacological agents is clinically useful remains 
unknown. Within the perspective of substance dependence, the authors also fail to discuss 
the implications of the increased extracellular NE in brain regions other than the PFC. 
Despite a number of effects of uncertain significance, atomoxetine remains a 
promising candidate. In fact it also possesses antidepressant and anxiolytic properties. 
Desipramine is another NE reuptake inhibitor that also possesses these beneficial effects. 
This could be especially significant in the treatment of addiction since depression and 
anxiety are often experienced during withdrawal and represent the primary cause for 
relapse (56). 
Animal Studies 
Substance dependence is usually characterized by cognitive impairments, 
especially in the withdrawal phase. Attenuating these deficits can increase the 
effectiveness of cognitive behavioral therapy, which will ultimately allow the patient to 
remain abstinent for longer periods of time. Davis and Gould (58) carried out the first 
experiment showing that ATO can reverse cognitive deficits in a mouse model of 
nicotine withdrawal. The procedure, lmown as fear conditioning, consisted in presenting 
an auditory signal to the mice, followed by a footshock. When expecting a noxious 
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stimulus, mice usually freeze in one position. By measuring the amount of time that the 
mice spent without moving, the investigators were able to determine if mice could learn 
to associate a painful event with the presentation of an environmental cue. Mice were 
subjected to chronic nicotine exposure, after which nicotine was eliminated and mice 
entered a phase of withdrawal. Mice receiving saline showed impaired fear conditioning, 
while the ones that received ATO showed a normal freezing behavior. This illustrates that 
ATO is capable of reversing fear conditioning deficits induced by nicotine withdrawal. 
Other animal studies using different models and experimental procedures have confirmed 
the potential therapeutic effects of ATO for nicotine dependence (59, 60). However, in 
the case of other types of addictions, it is not known if atomoxetine can be of therapeutic 
use. It has been reported that psychostimulant and opioid dependence also results in 
cognitive deficits ( 61 ), so the use of atomoxetine could be extended for other types of 
addictions. 
Instead of attempting to decrease cognitive deficits, studies with opioids and 
psychostimulants have employed ATO to attenuate drug craving. In a self-administration 
paradigm, Economidou et al. (62) trained rats to press a lever that delivered a dose of 
cocaine or heroin. Results demonstrated that ATO administered 20 minutes before a self-
administration session~ decreased significantly lever pressing for both substances. In 
another experiment, rats were trained to press the lever after the exposure to an 
environmental cue. Lever pressing caused an injection of cocaine. Following a period of 
abstinence, the environmental stimulus was presented without providing the lever. The 
time that the rats spent searching for the lever was a measure of drug craving and relapse. 
28 
Rats that were administered ATO 20 minutes before drug seeking sessiOns spent 
significantly less time looking for the cocaine lever after 1 week of abstinence. Other 
investigators have confirmed that ATO decreases craving for cocaine (63, 64, 65). The 
ability to extinguish addictive behaviors supports the idea that decreasing self-
administration is a manifestation of intact learning processes. This is in agreement with 
evidence suggesting that atomoxetine has cognitive enhancing properties in the animal 
brain. Because of the extensive evidence gathered by preclinical studies~ it can be 
concluded that ATO is effective in treating an animal model of nicotine and cocaine 
addiction. The support for the use of ATO is sufficient to legitimize studies on humans, 
the results of which are outlined below. 
Clinical trials 
In 2008 Stoop et al. (66) investigated the safety, tolerability and subject-rated 
effects of ATO in cocaine dependent individuals. After an ATO dose of 20 mg, the 
participants were asked to consume cocaine and give a subjective rating of their drug 
experience. Investigators also monitored heart rate, blood pressure, liver function and 
presence of side effects. ATO was able to decrease only the systolic blood pressure, while 
the subjective rating for cocaine effects did not change. ATO was therefore safe and 
tolerable in cocaine dependent individuals; however there was no evidence for an 
attenuation of drug liking. The authors argued that in order to see a statistically 
significant result, ATO doses should have been higher and maintained for longer periods 
of time. Successive studies employed larger doses of ATO. For example~ Levin et al. (67) 
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carried out a 12-week open clinical trial with ATO doses of 80 mg per day in ADHD 
patients with a comorbid cocaine dependence. While ATO was able to reduce ADHD 
symptoms, cocaine use was not attenuated, as demonstrated by urine toxicology and self-
reports. Possible circumstances that prevented significant results were the short duration 
of the clinical trial and a small sample size. More promising results have been achieved in 
amphetamine users. ATO attenuated blood pressure and heart rate increases induced by 
d-amphetamine. ATO also decreased the subjective rating score for drug experience but a 
change in drug consumption was not measured ( 68). 
The only clinical trial investigating the effects of ATO on nicotine withdrawal has 
not produced satisfying results. The aim of the study was to establish whether ATO could 
decrease the craving for nicotine and attenuate attention deficits as a result of the nicotine 
withdrawal. Fifty participants were divided in two groups: those that smoked for the 
stimulatory effects of nicotine and those that smoked for relieving withdrawal symptoms. 
After being on an ATO regimen for seven days, the study subjects were kept from 
smoking overnight. Only the group that smoked for stimulation experienced decreased 
craving for nicotine, although ATO was not more efficacious than bupropion and 
varenicline. On tests that measured attention and vigilance, there was no difference 
between placebo and treatment with A TO. Based on these results, ATO can be a potential 
treatment only for a subset of smokers and does not compare to currently approved drugs 
for smoking cessation (69). 
A similar scenario can be depicted for the effects of ATO on alcohol drinkers. 
Wilens et al. (70) carried out a double-blind, placebo controlled clinical trial with 80 
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participants affected by ADHD and a comorbid alcohol addiction. After at least 4 days of 
abstinence from alcohol, the study subjects were administered ATO for twelve weeks. 
The results indicated that ADHD symptoms were successfully diminished, but relapse to 
heavy drinking did not differ between ATO and placebo. However, those in the treatment 
group decreased their total heavy drinking days by 26% compared to controls. This was 
the only evidence of positive results and it was sufficient to consider ATO useful for the 
treatment of alcohol addiction. The authors argued that a better study design could have 
given more satisfying results. For example, the sample size was too small and the study 
subjects were mainly Caucasian (88%), making their experimental groups not 
representative of the real population. 
A clinical trial in which ATO has almost completely failed is an open label study 
that assessed the safety and tolerability of ATO in marijuana users. Thirteen subjects 
seeking to terminate their addiction started the treatment regime but only eight completed 
the study. The percentage of abstinent days after treatment did not differ from baseline, 
although a trend towards reduction was observed. Urine samples could not confirm this 
trend, but the authors argue that the long half life of /19-THC might have been 
responsible for this effect. The most surprising finding was the incidence of mild to 
moderate gastro-intestinal adverse effects in 77% of the subjects. Withdrawal symptoms 
from an attempted decrease in consumption might have caused this unusual outcome. The 
authors argue that based on these results there is no evidence for any therapeutic effect of 
ATO in marijuana users that seek treatment (71 ). 
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Summary 
After considering the results from both amphetamine and cocaine studies, it is still 
too early to reach a conclusion on the efficacy of ATO in treating psychostimulant 
dependence. In the future, larger clinical trials should take the next step and determine if 
ATO can decrease craving and cognitive deficits resulting from a cocaine or 
amphetamine addiction. 
For other substances such as nicotine, ATO does not seem to be effective. Animal 
models of nicotine withdrawal provided strong evidence for the use of ATO, but results 
from the clinical trials did not match the expectations. ATO was effective only in a 
portion of the population and even in that subgroup, it was equivalent to already existing 
medications. However, given that only one nicotine study has been conducted, larger 
clinical trials should verify these results. Potential alterations to the study design might 
include more variety in the severity of withdrawal and other types of behavioral tests 
measuring nicotine craving. 
Animal studies using ATO for alcohol dependence have not been produced yet. On 
the other hand a clinical trial has been conducted and results demonstrated that ATO was 
only partially effective in prolonging abstinence from drinking. The authors believed that 
the characteristics of the study participants and the low number of abstinent days were the 
reason for the unsatisfying nature of the results. While these concerns are certainly 
influential, it must be reminded that all study participants also had ADHD. Therefore 
future studies should try to enroll habitual drinkers that do not have other conditions. This 
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patient population might find ATO more effective in decreasing consumption of alcohol 
compared to patients that have multiple disorders. 
Finally, clinical trials on marijuana dependent individuals yielded inconclusive 
results after the occurrence of adverse events in the majority of the study participants. 
While this unusual event might have been a result of withdrawal symptoms, another 
possibility is a potential interaction between ATO and marijuana. Animal studies co-
administering ATO and 119-THC might be able to verify if this interaction is real. If not, 
future studies should try to administer ATO through a different formula or route, with the 
intent of bypassing the digestive system and preventing GI side effects. 
Reboxetine 
Mechanism of action 
Reboxetine is an antidepressant currently approved in Europe for the treatment of 
clinical depression and ADHD (72). It is a potent and selective inhibitor of the 
norepinephrine (NE) reuptake transporter, with almost no affinity for the dopamine (DA) 
and serotonin transporters. Even though reboxetine increases the levels of NE in the 
synapse, the ultimate effect is a decrease in firing and neurotransmitter releasing rate. 
This is due to the presence of a.2 adrenergic autoreceptors on cell bodies and axon 
terminals, which get overactivated by high levels of extracellular NE and cause an 
inhibition of noradrenegic neurons. The locus ceruleus (LC) is the brain region mostly 
affected by reboxetine, where NE release is dose dependently decreased in both acute and 
long term administration (73). 
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The LC is especially susceptible to opioid drugs, where an acute exposure causes a 
decrease in the cAMP pathway followed by a decrease in firing rate. It is hypothesized 
that a compensatory mechanism is capable of overstimulating the cAMP pathway after a 
chronic exposure to opioids, ultimately resulting in an increased release of NE. The 
enhanced activity of these neurons after chronic exposure is believed to be the cause of 
withdr~wal symptoms (74). Reboxetine might represent a potential therapeutic agent for 
its ability to decrease the release ofNE from LC projections. 
Reboxetine also possesses affinity for nAChRs, although binding is not competitive 
with acetylcholine. In particular reboxetine seems to target receptors that contain the a.3-
P4 subunits in hypothalamic synaptosomes. Non competitive binding to a.4-P2 containing 
receptors was also documented in thalamic synaptosomes (75). In virtue of this properties 
reboxetine is being tested as a treatment of nicotine dependence. 
Animal Studies 
The only laboratory study examining the effects of reboxetine on an animal model 
of substance dependence was carried out by Rauhut et al. in 2002 (76). In their first 
experiment, rats were trained to self administer nicotine or sucrose. Upon an acute 
administration of reboxetine, self administration of nicotine decreased by 60% relative to 
baseline. On the other hand, the sucrose treatment group reduced their intake by 20%. 
These results indicate that reboxetine has specificity for nicotine and has little impact on 
the food-reward neurocircuitry. 
34 
The effects of long term treatment were also assessed. 14 days of reboxetine 
reduced both nicotine and sucrose self administration without eliciting tolerance in all of 
the animals. On the fifteenth day, the reboxetine treatment group was given a dose of 
saline and the nicotine intake increased to control levels. This confirmed that reboxetine 
was necessary to maintain a low nicotine self-administration. 
In order to strengthen the validity of the results, the authors had to make sure that 
the decrease in nicotine self-administration was not due to a potential sedative effect of 
reboxetine. All rats were pretreated with reboxetine and successively divided in groups 
that received either nicotine or saline. Nicotine increased locomotion compared to saline, 
confirming that reboxetine does not have general sedative effects. A more direct evidence 
would have resulted from a measurement of sedation between reboxetine and saline 
treatments, which however was not carried out by the authors. 
The results produced by Rauhut et al. suggest that reboxetine attenuates nicotine 
intake in animals. Based on their findings, it appears that reboxetine does not induce 
tolerance, is specific in maintaining a low self-administration of nicotine and does not 
produce general sedation. Therefore, both studies on the mechanism of action and studies 
on animal models support the idea that reboxetine might work in humans as a smoking 
~essation agent. On the other hand, unanswered questions remain as to whether 
reboxetine can attenuate the effects of other addictive drugs. Due to its ability to impact 
the noradrenergic transmission of the LC, future animal studies should begin with 
research involving opioid dependence. 
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Clinical studies 
Even though preclinical studies provided support for the use of reboxetine in 
smoking cessation, clinical trials have explored its use in other types of substance 
dependence. Szerman et al. (77) have investigated the effects of reboxetine in 26 cocaine 
dependent patients seeking treatment. Urine toxicology, cocaine dependence, depression 
and anxiety were monitored during the 12 weeks of reboxetine administration. The data 
was taken from 20 participants and results showed a statistically significant effect of 
treatment in decreasing cocaine use compared to baseline. However, the authors pointed 
out that the participants able to complete the clinical trial were more likely from the start 
to remain abstinent. They suspected that the participants with more severe withdrawal 
symptoms dropped out of the study probably due to inefficacy of treatment. In fact 
individual susceptibility strongly influences the severity of a cocaine withdrawal 
syndrome. While the participants completing the trial found reboxetine to be beneficial, 
therapeutic efficacy on individuals with severe withdrawal symptoms is unknown. 
Other promising results have been achieved by a recent clinical trial, which 
determined that reboxetine can attenuate the effects of MDMA. Cardiovascular related 
changes such as NE plasma levels, heart rate and blood pressure were all decreased in 
subjects pretreated with reboxetine. Drug high, stimulation and emotional excitation were 
also reduced in the treatment group. The authors ruled out a possible inhibitory 
pharmacokinetic interaction between reboxetine and MDMA, which could have 
explained the decrease in drug high. The treatment group actually had higher plasma 
levels of MDMA and its active metabolite 3,4-methylenedioxyamphetamine. Therefore 
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the authors confirmed that reboxetine can pharmacologically attenuate the effects of 
MDMA(78). 
The evidence emerged from these clinical trials provides support for the use of 
reboxetine in psychostimulant dependence. However larger clinical trials are needed to 
consolidate this hypothesis. In the case of cocaine dependence, more attention should be 
paid to those individuals affected by severe withdrawal symptoms. Even if reboxetine 
alone turns out to be ineffective in this patient population, it might serve as an effective 
supplement to other kinds of therapies. Successive studies should explore the use of 
reboxetine in conjunction with cognitive behavioral therapy or in conjunction with other 
pharmacological agents. After considering the above results, it appears that the reuptake 
of NE has a major role in the neurobiology of psychostimulants. While future clinical 
studies should continue in this direction, there is an urgent need for clinical trials on 
smoking cessation. The ability of reboxetine to antagonize nACbR has yet to be 
examined in humans despite the abundant evidence emerging from molecular studies. 
Selegiline 
Mechanism of action 
In the central nervous system, neurotransmitters such as DA, NE and serotonin 
are broken down by two enzymes, catechol 0-methyl transferase and monoamine 
oxidase. The latter is in turn is divided in the A (MAO-A) and B (MAO-B) types. While 
serotonin is mostly metabolized by the first type, DA and NE are equally broken down by 
both types. Selegiline is a potent irreversible MAO-B inhibitor and is currently used for 
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the treatment of Parkinson's disease (79). It binds covalently to the flavin portion of 
MAO-B (80), in regions where this enzyme is highly concentrated, namely the thalamus, 
cortex~ striatum and brainstem (81). At higher concentrations, selectivity is lost and both 
types of MAO are inhibited (82). Metabolism of DA by MAO-B causes the release of 
hydrogen peroxide, which contributes to the toxicity of addictive drugs that increase 
levels of DA. Thus, by inhibiting MAO-B selegiline has also a neuroprotective effect 
(79). 
One of the active metabolites of selegiline is L-methamphetamine, which is the less 
active enantiomer of the common street drug. L-methamphetamine blocks the reuptake of 
DA by inhibiting the DA transporter. It has 40% of the potency of selegiline in terms of 
increasing the levels of DA. Other active metabolites include L-amphetamine and 
desmethylselegiline (80). 
The ability to inhibit MAO and the presence of L-methamphetamine as an active 
metabolite allows selegiline to increase the extracellular levels of DA in parts of the 
meso limbic pathway. As such, selegiline can compensate for the lack of DA found in the 
midbrain after prolonged use of addictive drugs. Together with the above properties, the 
neuroprotective effects further supports the use of selegiline as a potential treatment for 
substance dependence. 
Animal studies 
Since selegiline produces its effects in multiple ways, He et al. (80) conducted an 
experiment that determined which of selegiline's mechanism of action was more 
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significant in treating an animal model of opioid dependence. Answering this question 
would have contributed to the development of a more targeted treatment with less 
adverse effects. The investigators used clorgyline, an MAO-A inhibitor, rasagiline, an 
MAO-B inhibitor, and L-methamphetamine. After a training in morphine self-
administration, rats were divided into control and treatment groups. Clorgyline and 
rasagiline were administered at two different doses. The lower dose (1.0 mg/kg) allowed 
selectivity for only one type of MAO, while the higher dose (1 0 mg/kg) was non 
selective. Both of the selective doses did not produce a significant effect compared to 
controls, whereas all other treatment groups experienced a decrease in opioid self-
administration. Taken together these results demonstrate that all of rasagiline's 
mechanisms of action are important and that only non-selective doses are effective. In 
addition;selegiline shows promise as a treatment for opioid addiction. 
Other studies confirmed the efficacy of selegiline in animal models of opioid 
dependence. Grasing and Ghosh (83) were able to attenuate behavioral deficits as a result 
of opioid withdrawal by pretreating rats with selegiline. After two or three weeks of 
morphine withdrawal, rats were subjected to a forced swim test (FTS), in which freezing 
behavior represents a measure of decreased central dopaminergic activity. Nucleus 
accumbens and striatal slices were obtained after the FTS. When they stimulated firing of 
neurons by perfusion with cocaine and amphetamine, DA efflux was decreased in 
animals that were withdrawn from morphine. Selegiline prevented both the decrease in 
DA efflux and immobility in theFTS. Results were significant for nucleus accumbens 
slices but not for striatal slices. The authors concluded that selegiline attenuates decreases 
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in DA efflux induced by opioid withdrawal and that the nucleus accumbes is more 
affected than the striatum during opioid withdrawal. 
Selegiline has also been used in alcohol self-administration studies. Cohen et al. 
(84) trained rats to distinguish between two levers, one that provided ethanol and one that 
provided water. All animals showed more than 90% preference for the ethanol lever. A 
series ofMAO inhibitors were used in the study, including ones that were specific to only 
one isoform of MAO and others that lacked specificity. Selegiline was used at doses of3 
and 10 mglkg, which according to Curet et al. (85), produced selectivity only for MAO-B 
in the rat brain. With other MAO inhibitors only nonselective doses were able to decrease 
self-administration. This led the investigators to confirm the evidence from previous 
studies suggesting the use of non-selective doses in order to obtain significant results. 
Selegiline was effective even at the selective dose because the metabolite !-
methamphetamine might have contributed to the increase in available DA (84). Previous 
studies had confirmed the ability of selegiline in decreasing alcohol self-administration in 
a mouse model (86). 
Similar animal studies with nicotine have not been carried out yet, but Siu et al. 
(87) discovered that selegiline strongly inhibits cytochrome P450 2A6 (CYP2A6), the 
major enzyme involved in the metabolism of nicotine. Individuals with a genetic 
deficiency in CYP2A6 are 1.75 times more likely to quit smoking because their body 
nicotine concentration takes longer time to fall and therefore these individuals are less 
likely to experience severe withdrawal. By inhibiting CYP2A6, selegiline slows down the 
metabolism of nicotine and therefore can work as a smoking cessation aid. By prolonging 
40 
the levels of nicotine in the body, it can potentially function as an adjuvant to a nicotine 
replacement therapy. 
Although promising results support the potential of selegiline in the treatment of 
multiple substance related disorders~ animal studies that employed psychostimulants have 
not produced satisfying evidence for its efficacy. Yasar et al. (88) demonstrated that an 
injection of selegiline did not alter D-amphetamine self-administration. Therefore the 
authors concluded that selegiline was not suited for the treatment of psychostimulant 
addiction. Experiments using methamphetamine and cocaine models of dependence 
produced similar results (89). 
Clinical Studies 
Numerous clinical trials have been published on selegiline, especially in cocaine 
dependent indivi4uals. Initial studies focused on its safety, tolerability, 
pharmacodynamics and pharmacokinetics. Aside from showing the absence of adverse 
effects and interactions between selegiline and cocaine, these preliminary studies also 
attempted to demonstrate the presence of therapeutic effects. An oral administration of 
selegiline was able to decrease the feeling of 'high' in cocaine dependent subjects (90). 
The transdermal patch was then introduced with the intent to: 1) avoiding first pass 
effect; 2) providing a more prolonged exposure; 3) reducing the levels of metabolites; 4) 
avoiding the inhibition of MOA in the intestine and liver- a known cause of adverse 
effects. The first study using this route of administration found that selegiline decreased 
only some of the physiological and subjective effects of cocaine (91 ). 
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These partially satisfying results were followed by a large clinical trial that 
specifically aimed at assessing the ability of selegiline to decrease cocaine intake. 300 
cocaine dependent subjects were enrolled in a double-blind, placebo-controlled study in 
which transdermal patches of selegiline were administered daily for 8 weeks. Relative to 
baseline, the selegiline treatment group decreased the number of abstinent days by 
11.4%, compared to a 14% in the placebo group. Urine toxicology and behavioral tests 
measuring the severity of substance dependence did not show a difference between the 
two treatment groups. Based on the results, transdermal patches of selegiline do not seem 
to work as a treatment for cocaine addiction (92). 
The most recent publication evaluated the potential benefits of transdermal 
selegiline with higher doses of cocaine to best resem~le the consumption usually found in 
cocaine addicts. Physiological effects of cocaine were unchanged with the administration 
of selegiline. Craving was reduced~ but the reward following drug use was not decreased. 
In agreement with previous evidence, this clinical study confirmed the inadequacy of 
transdermal selegiline as a treatment for cocaine dependence (93). 
Due to promising evidence from preclinical studies, selegiline has also been 
evaluated as a treatment for nicotine dependence. In a randomized double blind clinical 
trial, 109 habitual smokers were assigned to either a nicotine patch plus oral selegiline or 
just a nicotine patch. 25% of the first group remained abstinent for 52 weeks, compared 
to an 11% in the second group. However the results did not reach statistical significance. 
Tests for nicotine craving and the need for nicotine patches showed a significant effect of 
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selegiline. The authors believed that selegiline could not be excluded as a viable option 
for smoking cessation and expressed the need for more clinical trials (94). 
However successive studies could not validate the above findings. 51 subjects 
receiving oral selegiline hydrochloride for eight weeks did not achieve a greater smoking 
abstinence rate compared to placebo. While indices of nicotine withdrawal, dependence, 
craving and depression were decreased over time, these parameters did not differ between 
the two treatment arms. The reasons for these unsuccessful results were not clear. The 
authors indicated that the placebo group had an abnormally high percentage of abstinence 
compared to previous clinical trials. In addition, all of the study participants were mostly 
Caucasian with high educational achievements and a strong motivation to quit. Lastly, for 
the 6 months follow up data the participants in the study did not reach the required 
number for statistical power (95). Shortly after the publication of these re~ults, another 
clinical trial produced negative results. A transdermal patch of selegiline for 8 weeks did 
not improve smoking abstinence relative to placebo (96). 
Summary 
Cocaine studies suggest that selegiline is not an effective treatment option. Three 
of the four publications reviewed above could not achieve a significant effect for 
selegiline. Despite the negative results, some authors have tried to justify the inefficacy 
of selegiline by indicating various experimental conditions that could have compromised 
the findings. For example, Elkashef et al. hypothesized that the transdermal route of 
administration decreased the concentration of metabolites such as L-methamphetamine 
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and L-amphetamine, both of which could have had a crucial role in decreasing cocaine 
craving. Future clinical trials could return to the oral form of selegiline. In case the oral 
route turns out to be effective, it means that the active metabolites have a significant role 
in the pharmacology of selegiline in humans. Elkashef et al. also indicated that the study 
participants receiving selegiline in their clinical trial had been using cocaine for a longer 
period of time compared to cocaine users in the control group. This could have masked 
the effects of selegiline because of a more severe craving for cocaine. Even though the 
frequency of drug use during the 30 days prior to the clinical trial was the same across all 
individuals, this group difference might have influenced the behavioral aspect of their 
addiction. In other words, individuals that have been taking cocaine for longer periods of 
time probably have a more consolidated addictive behavior. Additional clinical trials 
could therefore adjust to this variable by creating the same average of past cocaine use 
across all treatment groups. 
Nicotine studies have produced findings of similar nature. Both publications could 
not achieve a significant effect of selegiline in all their experiments. Again, the 
characteristics of the participants recruited might have played a significant role. For 
example, in Weinberger et al., the placebo group had an abnormally high percentage of 
abstinence compared to previous clinical trials. In addition, all of the study participants 
were mostly Caucasian with high educational achievements and a strong motivation to 
quit smoking. This might have hindered a potential difference between treatment and 
placebo. A common theme in both cocaine and nicotine studies has been the objective of 
decreasing substance intake. Instead, it would be interesting to see if selegiline has any 
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use as a relapse prevention agent. Future clinical trials would have to enroll patients that 
have already started a period of abstinence, with or without the help of cognitive 
behavioral therapy. Lastly, the effects of selegiline in an opioid or alcohol dependent 
population have not been explored yet~ despite the compelling evidence gathered from 
animal studies. 
Modafinil 
Mechanism of action 
Modafinil is a wakefulness-promoting agent approved for the treatment of 
narcolepsy. Aside from its main usage, scientists are also testing this drug for its 
psychostimulant and neuroprotective properties. In fact modafinil is currently being 
employed in clinical trials for substance dependence, neurodegenerative diseases and a 
variety ·of psychiatric disorders. However, a clear mechanism of action has not been 
elucidated yet. Investigators have looked at numerous brain regions and molecular 
targets, but the results have been mostly inconclusive. 
After the completion of preliminary studies showing that modafinil has mild 
psychostimulant effects, Mignot et al. carried out binding assays with neurotransmitter 
transporters that are usually bound by cocaine and amphetamine. With the dopamine 
(DA) transporter modafinil was found to have only weak binding (97). Contrary to these 
findings, Madras et al. (98) demonstrated significant binding to striatal DA transporters in 
a rhesus monkey model. The ability ofmodafinil to affect the release ofDA has also been 
the subject of controversy. Simon et al. (99) found that both a tyrosine hydroxylase 
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inhibitor and DA receptor antagonists were not able to alter the effects of modafinil on 
locomotion, suggesting that the release ofDA is not affected. On the other hand, Winsor 
and Eriksson (100) made the opposite conclusion after showing that aDA autoreceptor 
antagonist blocked the effects of modafinil. Despite the diversity of results, most 
investigators agree on the fact that modafinil has a mechanism of action that is different 
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than the ones of classic psychostimulant drugs (101). For example DA receptor 
antagonists and a tyrosine hydroxylase inhibitor blocked the effects of amphetamine but 
could not inhibit moda:finil. L-DOP A co-administered with amphetamine caused a typical 
climbing behavior in mice, but not when co-administered with modafinil. Amphetamine 
was able to reverse reserpine-induced akinesia, while modafinil was not (99). Following 
·this rationale, investigators have also agreed that the effects on DA transmission cannot 
be solely responsible for the increased locomotor activity seen in the animal models, 
suggesting the existence of multiple molecular targets. 
Although a clear mechanism of action has not been described yet, the evidence so 
far reviewed still shows promise within the perspective of substance related disorders. If 
it is true that modafinil can increase the DA concentration within the striatum, then it can 
attenuate the decreases in striatal DA experienced during withdrawal from 
psychostimulants. At the same time~ its marked difference with cocaine and amphetamine 
suggests that modafinil will unlikely cause dependence. In fact a number of studies have 
confirmed that modafinil does not have abuse liability (1 01 ). 
Glutamate is another neurotransmitter that has been closely monitored as the main 
target of modafinil. Chronic exposure to substances of abuse causes a decrease in the 
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basal levels of extracellular glutamate in the nucleus accumbens (NAc) (102). At high 
concentrations, moda:finil increases the concentration of glutamate in the striatum (1 03). 
During abstinence, the initial decrease in extracellular glutamate in the NAc causes 
prefrontal cortex (PFC) projections to increase the release of glutamate. This process has 
been correlated with drug or cue induced reinstatement of drug seeking. It is 
hypothesized that the presynaptic stimulation of mGlut2/3 receptor· can decrease the 
release of glutamate, which therefore could prevent reinstatement of drug seeking. 
Moda:finil appears to increase the binding of glutamate to these receptors as demonstrated 
by an experiment showing that its effects were completely blocked by an mGlut2/3 
receptor antagonist (1 03). 
Moda:finil also affects other neurotransmitters. For example, Ferraro et al. found 
that moda:finil decreases GABA in the pallidum and striatum, another mechanis~ that 
could be responsible for increasing locomotor activity (103).. Moda:finil also shows 
binding to the NE transporter with an affinity that is comparable to that for the DA 
transporter. Since the adrenergic system is known for mediating the release of glutamate 
in the PFC, it is hypothesized that the effect of moda:finil on glutamatergic transmission 
might be exerted indirectly through NE (101). 
The mechanisms of action reviewed above have been limited to the ones most 
pertinent to the treatment of substance dependence. However, it is possible that the wake-
promoting and neuroprotective properties acting on different parts of the brain can 




Most of the animal studies on moda:finil have focused on opioid and cocaine 
dependence. Tahsili-Fahadan et al. (102) obtained compelling results with a rat model by 
investigating the ability of moda:finil to block opioid seeking behavior. The experimental 
procedure, called conditioned place preference (CPP), involved the use of two 
communicating chambers each with distinguished features. In the first session of the 
experiment rats were injected morphine or moda:finil and placed in one of two chambers. 
In the second session, the rats were injected with saline and then positioned in the other 
chamber. The rats were therefore trained to associate a specific substance with a specific 
environment. After the training period, the treatment doses were eliminated and the rats 
were given the opportunity to chose which chamber to go into. As predicted, the animal 
preferred the environment associated with morphine. In contrast, modafinil trained rats 
did not show CPP, which indicates that this drug does not have abuse potential and does 
not cause a reward. In the second experiment the rats underwent an extinction phase, 
where injections were terminated and the rats eventually lost preference for the 
morphine-associated chamber. An injection of morphine re-established CPP, but a 
pretreatment with modafinil blocked this effect. The authors concluded that modafinil has 
the ability to attenuate morphine induced reinstatement. To further investigate the effects 
of moda:finil, a group of rats was pretreated with moda:finil during the morphine training 
phase without undergoing extinction. Morphine was able to induce CPP, demonstrating 
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that modafmil only affects relapse and does not attenuate opioid seeking behavior during 
a period of daily drug intake. 
Because this was the first report of moda:finil on opioid dependence, it is still early 
to make a conclusion on its potential benefits. Based solely on the results from the above 
study, modafinil shows promise in prolonging abstinence from opioids. The only 
negative outcome in this study was the increase in morphine induced CPP with a smaller 
dose of moda:finil, the cause of which is still not clear. Future experiments should keep 
assessing the effects of modafinil at low doses to shine more light on this unexpected 
outcome. Another insightful project would be assessing relapse prevention through other 
types of protocols, such as drug or cue induced reinstatement of self-administration after 
an extinction phase. Studies on relapse prevention are more likely to succeed as 
experiments carried out during daily drug intake have not yielded positive results. 
While only one report has explored the effects of modafinil on opioid dependence, 
more studies have been conducted on cocaine. Deroche et al. (104) found that modafinil 
did not potentiate or weaken cocaine self-administration. After extinction, rats pretreated 
with moda:finil did not decrease the reinstatement of cocaine self-administration upon a 
cocaine injection. Other negative results have been produced by Bernardi et al. (1 05) who 
demonstrated that moda:finil increased cocaine CPP. Because of the unsatisfactory data, 
both authors believe that moda:finil should not be recommended for the treatment of 
cocaine dependence. 
Contrary to the above findings, other investigators believe that moda:finil might 
have a therapeutic potential. Newman et al. (106) used a discrimination study, where 
49 
animals were trained to differentiate cocaine from saline. Monkeys receiving an injection 
of cocaine had to press a lever in order to obtain food. A different lever was associated 
with a saline injection. In the experimental session, after an injection of moda:finil, 
monkeys pressed the lever previously associated with cocaine, suggesting a similar effect 
for both drugs. From a second experiment, the investigators found that moda:finil at 32 
mg/kg/day can decrease self administration of cocaine given at 0.0032 mg/kg and at 0.01 
mg/kg. This was the main outcome of the study, which was used by the authors to justify 
their recommendation of moda:finil for addiction treatment. In the last experiment, after 
completion of a cocaine self-administration regimen, saline was substituted in the 
injections. Self-administration slowly decreased, until it reached negligible values. Upon 
an injection of moda:finil, self-administration of saline returned back to elevated levels. 
This was evidence that moda:finil can elicit past cocaine seeking behavior. 
The results demonstrate a strong link between moda:finil and cocame. The 
similarity between the two drugs is considered by the authors as an advantage for 
treatment. In fact, as evident from their discussion, the authors seem to recommend 
moda:finil as a replacement therapy. At the same time, they dismissed the potential for 
abuse liability after observing that moda:finil shows a slow rate of onset. This line of 
thought is flawed since modafinil cannot possibly be a replacement therapy without being 
reinforcing to some extent. The major flaw might reside in the results showing the effects 
of moda:finil and cocaine are similar. In fact these findings are in contrast with previously 
described studies, which highlight the marked difference between psychostimulants and 
moda:finil. A possible reason for obtaining different results might be due to the use of low 
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doses. As previously illustrated in Tahsili-Fahadan et al., low doses of modafinil might 
have opposite effects compared to higher doses. 
Aside from a flawed reasoning, the results from the third experiment further 
questions the usefulness of modafinil. The fact that the monkeys relapsed to a cocaine 
seeking behavior is certainly a negative outcome. Finally, a total of eleven animals were 
used for the research, a number that would be appropriate only for a preliminary study. 
While it appears that modafinil does not have the ability to treat cocaine dependence in 
animal models, only larger studies will be able to confirm it. For future research, it would 
be interesting to see whether modafinil is capable of preventing relapse, a factor that 
plays a major role in the treatment of addiction. 
Clinical studies 
A preliminary clinical study provided evidence that modafmil can increase cocaine 
abstinence compared to placebo (1 07). However, more robust studies were needed to 
confirm these results. In a study published in 2009, Anderson et al. (108) showed that 
modafinil is only partially effective in the treatment of cocaine dependence. 210 
participants were randomly divided in groups receiving either placebo, modafinil at 
200mg or 400mg. The treatment was administered once daily for 12 weeks in conjunction 
with cognitive behavioral therapy once a week. The main outcome measure was percent 
. of cocaine non-use days as reported by self-assessment and confirmed by urine tests. 
After completion of the study, the modafinil groups did not differ from controls. No 
difference was also found in urine tests. However, the maximum number of consecutive 
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non-use days was increased in the participants taking moda:finil. Positive results were 
also found in a number of behavioral tests measuring addiction severity and cocaine 
craving, where 200mg of modafinil was shown to be partially effective. However, 
because the main outcome gave results contrary to the hypothesis, the authors decided to 
carry some post hoc tests. They noticed that in Dackis et al. (107), alcohol dependence 
represented one of the exclusion criteria during the recruitment of patients. For this 
reason, Anderson and colleagues decided to re-analyze the data without the participants 
that had a drinking addiction. Both percent of cocaine non-use days and maximum days 
of abstinence were significantly higher in the modafinil group compared to placebo. The 
authors therefore concluded that moda:finil can be effective only in a portion of the 
cocaine dependent population due to a suspected interaction between alcohol, cocaine 
and modafinil. 
While the potential of modafinil in the treatment of cocaine addiction remains 
unknown, more satisfying results emerged from a study conducted by Ghahremani et al. 
(1 09). The effects of modafinil between 16 abstinent methamphetamine (MA) dependent 
patients were compared to the ones of 19 healthy individuals. The main outcome was the 
percentage of correct responses in a behavioral test, where participants were shown a 
picture and asked to chose one of two possible answer keys. Upon a correct response a 
blue light turned on, while a red light indicated an incorrect choice. Some pictures 
inverted their correct answers without any warning during the course of the test. 
Therefore the participants were not only being tested in their ability to learn a task, but 
also whether they were mentally flexible to switch the correct answer. Both MA 
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dependent and healthy individuals were tested at baseline, showing a supenor 
performance by the healthy individuals. In the second part of the study, 200 mg of 
modafinil or placebo were administered two hours before the test to both groups. 
Modafinil increased the accuracy for the MA dependent group up to control levels, while 
healthy individuals did not experience a change in their performance. During each test, 
the brains of the study subjects were subjected to fMRI scans, which showed an increased 
activation of the anterior cingulate complex (ACC) in MA dependent subjects taking 
modafinil. None of these changes were encountered when placebo was administered and 
never emerged in the fMRI scans of healthy subjects. Other studies showed similar 
results to the ones examined above (11 0). 
Summary 
From the evidence collected so far it is not clear whether modafinil can be used to 
treat cocaine dependence. Ideally a treatment needs to be effective for the whole patient 
population, something that modafinil fails to do. Yet it seems like modafinil still has 
some beneficial effects, which prevents from excluding it as a possible candidate for 
substance dependence treatment. More studies are needed to uncover the various 
I 
unknowns regarding modafinil. The fact that it is effective for sleeping disorders suggests 
that the oral route of administration is capable of providing the right concentration in the 
brain. Therefore future studies using different routes of administration are unlikely to 
succeed. The 200 mg dose is also something that should not be altered in future research, 
since the 400 mg was not superior in any of the experiments conducted. Because of the 
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suspected interaction between modafinil, cocaine and alcohol, animal studies would be 
required to verify whether this interaction is real. Finally, since strong results were not 
obtained on the ability of moda:finil to decrease cocaine use, additional studies could 
direct their attention to relapse prevention. This is a very plausible option given that 
modafinil has mild psychoactive properties, something that a drug for the treatment of 
cocaine dependence should have. 
From the evidence gathered so far on methamphetamine studies, it appears that 
modafinil can improve learning in MA dependent individuals. However, more clinical 
trials are needed, especially ones that can recruit a higher number of patients. All studies 
produced so far have had a small number of participants. The next question to be 
n ' 
answered is whether modafinil can increase abstinence in MA dependent subjects 
undergoing cognitive behavioral therapy. The need for these additional studies is also 
supported by the results coming from the fMRI scans. It is lmown from earlier 
publications that MA dependent patients experience a decreased activation of the ACC 
during cognitive tests of control and vigilance. The ACC has also been correlated with 
' 
improved performance in the behavioral tests like the one used by Ghahremani et al. 
Thus, the fact that the MA dependent patients experienced an increased activation of the 
ACC during the study is a significant achievement. Modafinil thus shows promise as a 
supplement to cognitive behavioral therapy in MA dependent subjects. Another possible 
route to be investigated is the potential benefits of modafinil in decreasing MA 
consumption or relapse. However the incentive to pursue this direction is hindered by 
inconclusive results from cocaine studies. 
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DISCUSSION 
Cognitive enhancers represent a new approach to the treatment of substance 
dependence. They often have mechanisms of action similar to addictive drugs, which 
allows them to either decrease drug consumption or increase the rate of abstinence. Some 
cognitive enhancers target neurotransmitter systems more specifically involved with 
cognitive function, compensating for the deficits resulting from long term exposure to 
addictive substances. 
Among all the cognitive enhancers reviewed so far, selegiline has the most 
interesting mechanism of action due to the variety of changes that it causes in the brain. 
The function that is most relevant to substance dependence is the decrease in DA 
breakdown by inhibition of MAO. There is reason to believe that targeting MAO would 
be beneficial in a brain that has decreased levels of DA in the mesolimbic system. 
Another interesting function is the decrease in hydrogen peroxide as a result of the MAO 
inhibition. This allows selegiline to have neuroprotective properties, especially because 
MAO is found in the mitochondri~ where oxygen radicals are especially harmful to the 
survival of a cell. Investigators have also found other neuroprotective effects that are not 
related to the inhibition of MAO, which contribute to its use in Parkinson's disease and as 
a potential treatment for addiction (79). 
The extensive literature on the putative function of selegiline has encouraged 
researchers to conduct a significant amount of animal studies. Most of them have shown 
promising results. However, clinical trials did not test selegiline on the same addictive 
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drugs used in the animal models. For example selegiline shows efficacy in treating 
animal models of opioid and alcohol dependence, but not for cocaine and nicotine. 
Clinical studies have focused on cocaine and nicotine, without achieving successful 
results. Investigators have not yet conducted clinical research on opioid and ethanol 
addiction. To summarize, even though selegiline appears to be ineffective in cocaine and 
nicotine dependent humans, it might prove to be therapeutic in other kinds of addiction. 
The potential of this pharmacological agent remains to be further investigated. 
Research on modafinil also needs to be further delved into. The available 
information on this drug makes it one of the most exciting cognitive enhancers to 
investigate. Its mechanism of action is still not fully elucidated, due mostly to the 
multiplicity of neurotransmitter system that it affects. Contrary to the case of selegiline, 
animal studies have been influential in directing the clinical trials. Cocaine studies in rats 
and monkeys have been followed by similar studies in humans. Results from the latter 
show that modafinil decreases consumption only in the absence of a comorbid alcohol 
addiction. Therefore the efficacy of moda:finil in cocaine dependence remains uncertain 
and more research is needed for a final consensus. The wake promoting and cognitive 
enhancing properties of modafinilled to the idea of using it to reverse cognitive deficits 
found in withdrawal from addictive drugs. Animal studies that can prove this idea still 
need to be conducted. In clinical trials however, modafinil has been the only cognitive 
enhancer tested for modifying cognitive function in humans during a period of 
abstinence. The results indicate that modafinil is effective in enhancing cognitive 
functions, making it the most exciting project in substance dependence research. 
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Reboxetine is the cognitive enhancer that has the highest success rate in clinical 
trials, even though this might be due to the fact that only preliminary studies have been 
conducted. Substances that cause dependence, such as cocaine and amphetamine, 
increase NE transmission. On the other hand, reboxetine dampens the levels of synaptic 
NE by indirectly stimulating a2 adrenergic autoreceptors. Therefore, by causing changes 
in the brain that are opposite to ones caused by addictive drugs, reboxetine is unlikely to 
cause dependence and it is a good candidate for treating substance related disorders. 
Another molecular target of reboxetine is the nAChR. Investigators conducted an 
experiment aimed at decreasing nicotine self-administration in a rat model. Even though 
results from this study were encouraging, clinical trials have not verified if reboxetine 
works as a smoking cessation agent. 
One clinical trial in patients with cocaine addiction and another one in patients 
with MDMA addiction have been conducted, both of which show that reboxetine is 
effective. Although still in the preliminary stage, these studies make reboxetine a 
promising cognitive enhancer for attenuating the effects of psychostimulants. In fact none 
of the literature on the other drugs reviewed so far have achieved results of comparable 
success. 
Research with Atomoxetine has made the least progress compared to other 
cognitive enhancers. The major difficulty has been trying to translate its efficacy from the 
laboratory to the clinic. Aside from acting on brain regions responsible for cognitive 
function, atomoxetine also has anti-depressant effects. These qualities led to animal 
studies that tried to improve cognitive function and decrease consumption of cocaine. In 
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both cases investigators generated the most convincing evidence out of all the animal 
studies conducted on cognitive enhancers. This success was surprisingly not reflected in 
the human condition. Atomoxetine could not maintain abstinence from alcohol drinking 
and it was not superior to already existing medications for smoking cessation. In 
marijuana users it was not effective and it caused adverse side effects. Lastly, preliminary 
studies seemed encouraging for amphetamine users but not for cocaine users. 
A review of the available literature on cognitive enhancers has pointed out that 
numerous clinical trials have been conducted with minimal preclinical evidence. This 
discrepancy probably originated from the fact that many of the cognitive enhancers under 
investigation have already been approved for other pathological disorders. Because these 
medications are safe and tolerable, going straight to the clinical trial might be a more 
direct way to assess the efficacy of a drug. The caveat is that the therapeutic potential of 
some cognitive enhancers is unknown before being tested on humans. Therefore a 
classical dilemma in medical research arises. On one hand, the translational aspect of 
medicine has been recognized as the standard approach that best predicts the success of a 
clinical trial. According to this approach, animal studies should precede clinical studies. 
On the other hand, there are numerous examples of animal studies that are not good 
predictors of success in clinical trials - as in the case of atomoxetine. Therefore one could 
also argue for a more 'trial and error' approach. 
What remains certain is that the potential of cognitive enhancers has yet to be. 
revealed. This is especially true regarding the ability to ameliorate cognitive deficits 
experienced during abstinence. Future clinical studies will hopefully learn from the 
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mistakes of the past and uncover new therapeutic effects for this class of drugs. The 
present thesis was able to examine only four pharmacological agents, but others cognitive 
enhancers such as memantine and galantimine are also under investigation. Research 
conducted in the upcoming years will continue to feed excitement and progress in the 
discovery of a treatment for substance dependence. 
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